AzTrials
AzTrials

PreTerm NeonateNCT06901206

Neonatologist-Performed Lung Ultrasound (NPLUS) to Guide Respiratory Therapy

A study testing Neonatologist performed lung ultrasound in people with PreTerm Neonate and Respiratory Distress Syndrome (RDS), run by Royal Hospital For Women at 1 site in Australia.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this cross-over clinical trial is to evaluate whether Neonatologist-Performed Lung Ultrasound (NPLUS) can be used in preterm babies on non-invasive breathing support to reduce the amount of oxygen they need. Read more about this study

Who is it for?
Ages 1 week and older
What is being tested?
Neonatologist performed lung ultrasound
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteAustralia
Study dates
Mar 2025to Jun 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 week and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • All preterm infants (<33 weeks gestational age) from their 2nd week of life, receiving respiratory support via NCPAP
  • expected to stay on NCPAP for the following 5 days at the NICU, Royal Hospital for Women, Randwick, Sydney
  • provided written informed consent obtained from parents.

Who cannot join

  • Neonates with previous abdominal surgery
  • Major congenital anomalies.
  • >33+0 weeks
  • Less than 1 week of age
  • Invasive ventilation
  • Bilevel or Multilevel non-invasive ventilation
  • Not expected respiratory support via CPAP for the following 5 days.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Tim Schindler BMedSc MBBS FRACP PhD contact

+61293826190

tim.schindler@health.nsw.gov.au

Viktoria Gruber, Dr.med.univ. contact

+436649703521

vi.gruber@medunigraz.at

Australia1 site
  • Newborn Intensive Care Unit, Royal Hospital for Women

    Sydney, New South Wales, 2031

    Tim Schindler BMedSc MBBS FRACP PhD, • +61408394008, tim.schindler@health.nsw.gov.au

    Meredith Ward BMedSc MBBS, FRACP, +61414774914, Meredith.ward@health.nsw.gov.au

Other trials in Australia

About this study

Official title: Neonatologist-Performed Lung Ultrasound (NPLUS) to Guide Respiratory Therapy on Non-Invasive Ventilation in Preterm Infants

The goal of this cross-over clinical trial is to evaluate whether Neonatologist-Performed Lung Ultrasound (NPLUS) can be used in preterm babies on non-invasive breathing support to reduce the amount of oxygen they need. The main question it aims to answer is:

When a baby's oxygen requirement goes up, does NPLUS help to target interventions and reduce oxygen requirements?

Read more

Researchers will compare NPLUS to standard treatment.

Participants will:

Have a lung ultrasound performed whenever their oxygen requirement increases by more than 10%.

The ultrasound findings will be used to target interventions that aim to improve air entry in the lungs.

Each time this happens, the researchers will note what happens to the oxygen requirement afterwards.

Each participant will participate for five days. For the first two days, they will be randomized to either the NPLUS arm or the usual care arm.

There is then a 24 hour period of usual care. For the final two days, participants cross over to the other arm of the trial.

Read the detailed description

NPLUS is used to detect various artifacts that emerge due to air and fluid ratio in the lungs. The image results form a beam reflection and reverberation of echoes on tissues. The most important artifacts display A-lines, B-lines and the pleural line with the lung sliding. A-lines (horizontal, hyperechogenic long line reverberation artefacts of the pleura) are a sign of aeration. B-lines (vertical, hyperechoic ring-down artefacts arising from the pleural line) indicate fluid in the interstitial space. The pleural line is a smooth, hyperechoic line. Breathing or ventilation causes a movement of the pleural sheets resulting in a visible sliding as definitive sign of lung aeration and ventilation.

Lung consolidations can be sonographically detected by an absence of the pleural line and therefore the lung sliding and areas with loss of aeration visible as lung with tissue like density. Consolidations can be caused by several conditions (e.g., atelectasis, pneumonia, contusion) and the differentiation can be done by ultrasound.

Preterms are prone for recurrent episodes of loss of aeration due to small airway size and muscular weakness. Lung ultrasound has established in the last years and has become an emerging tool for bedside evaluation and to dynamically assess the lungs in several respiratory conditions. Detecting loss of aeration via lung ultrasound is fast and feasible. Trials have investigated the role of lung ultrasound to guide surfactant admission and extubation failure.

To our knowledge there is no evidence investigating the feasibility of lung ultrasound to guide respiratory therapy for preterms on non-invasive ventilation. Oxygen exposure is associated with numerous complications in preterms and should be maintained as low as possible. Lung ultrasound could be a promising tool for a faster detection of loss of aeration and due to more targeted intervention with the ultrasound knowledge a faster FiO2 reduction could be achieved.

The main objective of this study is to evaluate, if NPLUS performed according to a standardized protocol (lung ultrasound score, LUS) in preterm neonates with an absolute increase ≥ 10% over their baseline FiO2 on non-invasive ventilation can detect loss of aeration resulting in more effective reduction of FiO2 demand through targeted interventions (e.g., temporary PEEP increase for alveolar recruitment, positioning of the patient) compared to routine care.

The present study is a cross-over study evaluating the use of NPLUS to guide respiratory therapy of preterm infants on non-invasive ventilation. After inclusion of the study patient, an observation time of two 48-hour blocks and a washout phase of 24 hours between these two blocks is set. Each 48-hour block is managed according to the assigned treatment (NPLUS or standard care). In the 24-hour washout phase no study-related interventions are performed. The treatment assignments are swapped after the washout phase and in the next 48 hours infants previously assigned to NPLUS receive standard care and infants previously assigned to standard care receive NPLUS. Within these set time periods, each episode of increased persisting (>10 min) FiO2 demand (absolute increase ≥ 10% over the FiO2 baseline) on non-invasive ventilation is defined as event (e.g., patient 1, event 1). For each event, T0 is the time point when the absolute increase ≥ 10% over the initial FiO2 baseline was reported to the clinician and an intervention may be initiated, and T1 is the time point 1 h after T0. The clinician in charge is informed about the onset of every single event. In both treatment arms, interventions for every occurring event can be considered by the clinician in charge including targeted repositioning of the patient, temporary PEEP increase for alveolar recruitment, changes in ventilatory settings (e.g. change to Bilevel, NIPPV, NAVA), surfactant therapy, indication for a chest x-ray, and indication for thoracic physiotherapy.) In the 48-hour NPLUS block, lung ultrasound is performed at T0 (reported persistent increased FiO2 demand) and T1 (one hour after T0). NPLUS may be able to detect loss of aeration and lead to more targeted interventions to improve lung aeration. A comprehensive lung ultrasound examination will take 5 minutes or less to perform and involves minimal handling for the patient.

For each subject a baseline FiO2 is established for the control and NPLUS periods. The aim of using NPLUS versus standard care when managing an event is to reduce any increase from the subject's baseline in the resolution FiO2 level associated with the event.

The ratio of the FiO2 at resolution of each event to baseline FiO2 is a continuous measurement which is 1 when the resolution FiO2 equals the subject's baseline value. A ratio of 1.2 means the resolution FiO2 for the event is 20% higher than the subject's baseline FiO2, a ratio <1 indicates the resolution FiO2 for the event is less than the subject's baseline and so on.

Being tested
Neonatologist performed lung ultrasound
Keywords
NPLUS, Neonatologist performed lung ultrasound, lung ultrasound score, CPAP, loss of aeration, atelectasis, preterm neonate, respiratory distress syndrome
Medical subject headings
Respiratory Distress Syndrome, Pulmonary Atelectasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Neonatologist performed lung ultrasoundProcedure or surgery

    Neonatologist performed lung ultrasound is performed at T0 (reported persistent increased FiO2 demand) and T1 (one hour after T0). NPLUS may be able to detect loss of aeration and lead to more targeted interventions to improve lung aeration. A comprehensive lung ultrasound examination will take 5 minutes or less to perform and involves minimal handling for the patient.

Study groups in NCT06901206
Study groupRoleWhat they receive
NPLUSActive comparatorIn the NPLUS block, lung ultrasound is performed at T0 (reported persistent increased FiO2 demand) and T1 (one hour after T0). NPLUS may be able to detect loss of aeration and lead to more targeted interventions to improve lung aeration.
Receives: Procedure: Neonatologist performed lung ultrasound
ControlNo interventionRoutine Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean ratio res/base (Resolution FiO2 / Baseline FiO2)

    For each subject a baseline FiO2 is established for the control and NPLUS periods. Each episode of increased persisting (>10 min) FiO2 demand (absolute increase ≥ 10% over the FiO2 baseline) on non-invasive ventilation is defined as event.

    The aim of using NPLUS versus standard care (control) when managing an event is to reduce any increase from the subject's baseline in the resolution FiO2 level associated with the event.

    The ratio of the FiO2 at resolution of each event to baseline FiO2 is a continuous measurement which is 1 when the resolution FiO2 equals the subject's baseline value. A ratio of 1.2 means the resolution FiO2 for the event is 20% higher than the subject's baseline FiO2, a ratio <1 indicates the resolution FiO2 for the event is less than the subject's baseline and so on.

    Measured: Resolution FiO2 assessed 1 hour after increased persisting (>10 min) FiO2 demand (absolute increase ≥ 10% over the FiO2 baseline)

Secondary outcomes (9)
  1. Mean FiO2 (within 48-hour blocks)

    comparison of infants mean FiO2 in NPLUS vs. control period

    Measured: 48 hours

  2. FiO2 between T0 and T1

    Measured: Assessed 1 hour after increased persisting (>10 minutes) FiO2 demand (absolute increase ≥ 10% over the FiO2 baseline)

  3. LUS between T0 and T1

    Measured: Assessed 1 hour after increased persisting (>10 minutes) FiO2 demand (absolute increase ≥ 10% over the FiO2 baseline)

  4. Number of changes in ventilatory settings (PEEP)

    Total number of changes from baseline PEEP settings during each study period.

    Measured: 48 hours

  5. SpO2/FiO2 ratio

    Measured: 48 hours

  6. Routinely obtained capillary blood gas analysis (pH, pCO2)

    at certain time points within the study period.

    Measured: 48 hours

  7. Number of chest X-rays and NPLUS examinations, number of chest X-ray based interventions, number of NPLUS based interventions.

    Measured: 48 hours

  8. Number of recruitment maneuvers

    Number of recruitment maneuvers (e.g., repositioning of the patient, temporary PEEP increase for alveolar recruitment, changes in ventilatory settings (e.g.change to Nava), surfactant therapy, indication of a chest x-ray, and indication of thorax physiotherapy).

    Measured: 48 hours

  9. Time to detect impairment of lung aeration (consolidations).

    Measured: 48 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Mar 2025
  2. Study startMar 2025 (estimated)
  3. Primary completionMar 2026 (estimated)
  4. Study completionJun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06901206
Sponsor's protocol ID
2024/PID01756
Status last verified
Mar 2025
First submitted
10 Mar 2025
Last updated
28 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Neonatologist performed lung ultrasound in people with PreTerm Neonate and Respiratory Distress Syndrome (RDS), run by Royal Hospital For Women at 1 site in Australia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 28 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Tim Schindler BMedSc MBBS FRACP PhD (+61293826190, tim.schindler@health.nsw.gov.au), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean ratio res/base (Resolution FiO2 / Baseline FiO2) (time frame: Resolution FiO2 assessed 1 hour after increased persisting (>10 min) FiO2 demand (absolute increase ≥ 10% over the FiO2 baseline)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in